Literature DB >> 22807310

Evidence that nuclear factor IA inhibits repair after white matter injury.

Stephen P J Fancy1, Stacey M Glasgow, Meggie Finley, David H Rowitch, Benjamin Deneen.   

Abstract

OBJECTIVE: Chronic demyelination can result in axonopathy and is associated with human neurological conditions such as multiple sclerosis (MS) in adults and cerebral palsy in infants. In these disorders, myelin regeneration is inhibited by impaired differentiation of oligodendrocyte progenitors into myelin-producing oligodendrocytes. However, regulatory factors relevant in human myelin disorders and in myelin regeneration remain poorly understood. Here we have investigated the role of the transcription factor nuclear factor IA (NFIA) in oligodendrocyte progenitor differentiation during developmental and regenerative myelination.
METHODS: NFIA expression patterns in human neonatal hypoxic-ischemic encephalopathy (HIE) and MS as well as developmental expression in mice were evaluated. Functional studies during remyelination were performed using a lysolecithin model, coupled with lentiviral misexpression of NFIA. The role of NFIA during oligodendrocyte lineage development was characterized using chick and mouse models and in vitro culture of oligodendrocyte progenitors. Biochemical mechanism of NFIA function was evaluated using chromatin immunoprecipitation and reporter assays.
RESULTS: NFIA is expressed in oligodendrocyte progenitors, but not differentiated oligodendrocytes during mouse embryonic development. Examination of NFIA expression in white matter lesions of human newborns with neonatal HIE, as well active MS lesions in adults, revealed that it is similarly expressed in oligodendrocyte progenitors and not oligodendrocytes. Functional studies indicate that NFIA is sufficient to suppress oligodendrocyte progenitor differentiation during adult remyelination and embryonic development through direct repression of myelin gene expression.
INTERPRETATION: These studies suggest that NFIA participates in the control of oligodendrocyte progenitor differentiation and may contribute to the inhibition of remyelination in human myelin disorders.
Copyright © 2012 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22807310      PMCID: PMC3429638          DOI: 10.1002/ana.23590

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

Review 1.  Regulation of oligodendrocyte differentiation and myelination.

Authors:  Ben Emery
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

2.  Structural characterization of myelin-associated glycoprotein gene core promoter.

Authors:  I Laszkiewicz; B Grubinska; R C Wiggins; G W Konat
Journal:  J Neurosci Res       Date:  1997-12-15       Impact factor: 4.164

3.  Multiple roles of Id4 in developmental myelination: predicted outcomes and unexpected findings.

Authors:  Mireya Marin-Husstege; Ye He; Jiadong Li; Toru Kondo; Fred Sablitzky; Patrizia Casaccia-Bonnefil
Journal:  Glia       Date:  2006-09       Impact factor: 7.452

4.  Disruption of the murine nuclear factor I-A gene (Nfia) results in perinatal lethality, hydrocephalus, and agenesis of the corpus callosum.

Authors:  L das Neves; C S Duchala; F Tolentino-Silva; M A Haxhiu; C Colmenares; W B Macklin; C E Campbell; K G Butz; R M Gronostajski; F Godinho
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-12       Impact factor: 11.205

5.  Dysregulation of the Wnt pathway inhibits timely myelination and remyelination in the mammalian CNS.

Authors:  Stephen P J Fancy; Sergio E Baranzini; Chao Zhao; Dong-In Yuk; Karen-Amanda Irvine; Sovann Kaing; Nader Sanai; Robin J M Franklin; David H Rowitch
Journal:  Genes Dev       Date:  2009-06-10       Impact factor: 11.361

Review 6.  Pathogenesis of cerebral white matter injury of prematurity.

Authors:  O Khwaja; J J Volpe
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2008-03       Impact factor: 5.747

7.  Multiple sclerosis: re-expression of a developmental pathway that restricts oligodendrocyte maturation.

Authors:  Gareth R John; Sai Latha Shankar; Bridget Shafit-Zagardo; Aldo Massimi; Sunhee C Lee; Cedric S Raine; Celia F Brosnan
Journal:  Nat Med       Date:  2002-09-23       Impact factor: 53.440

8.  Distinct stages of myelination regulated by gamma-secretase and astrocytes in a rapidly myelinating CNS coculture system.

Authors:  Trent A Watkins; Ben Emery; Sara Mulinyawe; Ben A Barres
Journal:  Neuron       Date:  2008-11-26       Impact factor: 17.173

9.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2008-10-25       Impact factor: 79.321

10.  A myelin proteolipid protein-LacZ fusion protein is developmentally regulated and targeted to the myelin membrane in transgenic mice.

Authors:  P A Wight; C S Duchala; C Readhead; W B Macklin
Journal:  J Cell Biol       Date:  1993-10       Impact factor: 10.539

View more
  16 in total

1.  Apcdd1 stimulates oligodendrocyte differentiation after white matter injury.

Authors:  Hyun Kyoung Lee; Dylan Laug; Wenyi Zhu; Jay M Patel; Kevin Ung; Benjamin R Arenkiel; Stephen P J Fancy; Carrie Mohila; Benjamin Deneen
Journal:  Glia       Date:  2015-05-06       Impact factor: 7.452

Review 2.  Glial development: the crossroads of regeneration and repair in the CNS.

Authors:  Vittorio Gallo; Benjamin Deneen
Journal:  Neuron       Date:  2014-07-16       Impact factor: 17.173

3.  Daam2-PIP5K is a regulatory pathway for Wnt signaling and therapeutic target for remyelination in the CNS.

Authors:  Hyun Kyoung Lee; Lesley S Chaboub; Wenyi Zhu; Daniel Zollinger; Matthew N Rasband; Stephen P J Fancy; Benjamin Deneen
Journal:  Neuron       Date:  2015-03-05       Impact factor: 17.173

4.  Temporal Profiling of Astrocyte Precursors Reveals Parallel Roles for Asef during Development and after Injury.

Authors:  Lesley S Chaboub; Jeanne M Manalo; Hyun Kyoung Lee; Stacey M Glasgow; Fengju Chen; Yoshihiro Kawasaki; Tetsu Akiyama; Chay T Kuo; Chad J Creighton; Carrie A Mohila; Benjamin Deneen
Journal:  J Neurosci       Date:  2016-11-23       Impact factor: 6.167

Review 5.  Human embryonic stem cell-derived oligodendrocytes: protocols and perspectives.

Authors:  Walaa F Alsanie; Jonathan C Niclis; Steven Petratos
Journal:  Stem Cells Dev       Date:  2013-06-12       Impact factor: 3.272

6.  miR-219 Cooperates with miR-338 in Myelination and Promotes Myelin Repair in the CNS.

Authors:  Haibo Wang; Ana Lis Moyano; Zhangyan Ma; Yaqi Deng; Yifeng Lin; Chuntao Zhao; Liguo Zhang; Minqing Jiang; Xuelian He; Zhixing Ma; Fanghui Lu; Mei Xin; Wenhao Zhou; Sung Ok Yoon; Ernesto R Bongarzone; Q Richard Lu
Journal:  Dev Cell       Date:  2017-03-27       Impact factor: 12.270

Review 7.  Promoting remyelination for the treatment of multiple sclerosis: opportunities and challenges.

Authors:  Yueting Zhang; Taylor B Guo; Hongtao Lu
Journal:  Neurosci Bull       Date:  2013-04-05       Impact factor: 5.203

8.  Study on the Safety of Human Oligodendrocyte Precursor Cell Transplantation in Young Animals and Its Efficacy on Myelination.

Authors:  Haipeng Zhou; Siliang Lu; Ke Li; Yinxiang Yang; Caiyan Hu; Zhaoyan Wang; Qian Wang; Ying He; Xiaohua Wang; Dou Ye; Qian Guan; Jing Zang; Chang Liu; Suqing Qu; Zuo Luan
Journal:  Stem Cells Dev       Date:  2021-04-29       Impact factor: 3.272

9.  Nuclear factor I-A regulates diverse reactive astrocyte responses after CNS injury.

Authors:  Dylan Laug; Teng-Wei Huang; Navish A Bosquez Huerta; Anna Yu-Szu Huang; Debosmita Sardar; Joshua Ortiz-Guzman; Jeffrey C Carlson; Benjamin R Arenkiel; Chay T Kuo; Carrie A Mohila; Stacey M Glasgow; Hyun Kyoung Lee; Benjamin Deneen
Journal:  J Clin Invest       Date:  2019-10-01       Impact factor: 14.808

Review 10.  Mechanisms of oligodendrocyte regeneration from ventricular-subventricular zone-derived progenitor cells in white matter diseases.

Authors:  Takakuni Maki; Anna C Liang; Nobukazu Miyamoto; Eng H Lo; Ken Arai
Journal:  Front Cell Neurosci       Date:  2013-12-26       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.